The revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice!

Area of Science:

• Clinical Trials
• Regulatory Science
• Pharmaceutical Research

Background:

• The International Council for Harmonisation (ICH) has issued a draft of the Good Clinical Practice (GCP) Guideline E6(R3) for public review.
• The current E6(R2) guideline requires updates to accommodate evolving clinical trial methodologies and technological advancements.
• The revised guideline aims for broader applicability across various clinical trial designs and settings.

Purpose of the Study:

• To analyze the significant structural and content modifications in the ICH E6(R3) draft compared to E6(R2).
• To evaluate the anticipated impact of the E6(R3) guideline on all phases of clinical trial conduct, from initiation to completion.
• To identify the challenges associated with implementing the new GCP guideline within the Indian clinical research context.

Main Methods:

• Review of the draft ICH E6(R3) Good Clinical Practice Guideline.
• Comparative analysis of E6(R3) with the existing E6(R2) guideline.
• Assessment of implications for trial conduct processes, ethics committees, investigators, and sponsors, particularly in India.

Main Results:

• The E6(R3) guideline introduces substantial changes, impacting trial planning, execution, and reporting.
• Increased emphasis on core principles, digital technologies, ethical considerations, and quality management.
• Anticipated rise in responsibilities for ethics committees, investigators, and sponsors.

Conclusions:

• The ICH E6(R3) guideline represents a significant evolution in Good Clinical Practice standards.
• Successful implementation will necessitate adaptation by all stakeholders, including a focus on enhanced responsibilities.
• Specific challenges exist for implementation in India, requiring careful consideration and strategic planning.